Skip to main content
. 2023 Aug 24;13:13871. doi: 10.1038/s41598-023-41068-7

Table 5.

Multivariate survival analysis in HCC patients with high TBS undergoing surgical resection or transarterial chemoembolization (n = 299).

Overall survival Univariate analysis Multivariate analysis
HR CI p HR CI p
Age (≦66/ > 66 years) 0.975 0.758–1.255 0.845
Sex (male/female) 0.891 0.631–1.258 0.512
HBsAg (negative/positive) 0.998 0.774–1.285 0.249
Anti-HCV (negative/positive) 0.968 0.693–1.353 0.850
Albumin level (≥ 3.5/ < 3.5 g/dL) 1.567 1.201–2.044 0.001
Bilirubin level (≦1.1/ > 1.1 mg/dL) 1.536 1.155–2.043 0.003
ALT (≦40/ > 40 IU/L) 0.937 0.727–1.208 0.617
Creatinine (≦1.1/ > 1.1 mg/dL) 1.330 1.018–1.738 0.036
Platelet (≥ 150,000/ < 150,000/μL) 0.986 0.677–1.436 0.942
INR of PT (≦1.0/ > 1.0) 1.557 1.197–2.025 0.001
AFP (≦200/ > 200 ng/mL) 1.528 1.188–1.966 0.001 1.483 1.150–1.913 0.002
Performance status 0–1/2–4 1.638 1.212–2.215 < 0.001
ALBI grade 1/grade2-3 1.570 1.215–2.030 0.001 1.428 1.100–1.855 0.007
Vascular invasion (no/yes) 1.722 1.340–2.214 < 0.001 1.499 1.160–1.938 0.002
SR vs TACE 2.826 2.161–3.695 < 0.001 2.580 1.964–3.390  < 0.001

The forepart of the parentheses was set as the reference group in the univariate and multivariate analysis.

AFP ɑ-fetoprotein, ALBI albumin-bilirubin, ALT alanine aminotransferase, INR of PT international normalized ratio of prothrombin time, SR surgical resection, TACE transarterial chemoembolization, TBS tumor burden score.